Abstract

Introduction/BackgroundPoly(ADP-ribose)-polymerase inhibitors (PARPi) have changed the treatment landscape for high grade serous ovarian cancer. The CLIO trial (NCT02822157) evaluated olaparib (OLA) single-agent therapy versus physician’s choice chemotherapy (CT) in recurrent...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?
U.A Matulonis ... B.J Monk
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 28
U.A Matulonis, et. al.U.A Matulonis ... B.J Monk
01 Mar 2017
Abstract AS27: VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: preclinical and phase 1 data by the gynecologic oncology group
Bradley J Monk ... Joan L Walker
Clinical cancer research : an official journal of the American Association for Cancer Research | VOL. 21
Bradley J Monk, et. al.Bradley J Monk ... Joan L Walker
13 Aug 2015
Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)
Robert L Coleman ...
Clinical cancer research : an official journal of the American Association for Cancer Research | VOL. 24
Robert L Coleman, et. al.Robert L Coleman ...
01 Aug 2018
VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: Preclinical and phase I data by the Gynecologic Oncology Group.
Bradley J Monk ... Andrea Facciabene
Journal of Clinical Oncology | VOL. 31
Bradley J Monk, et. al.Bradley J Monk ... Andrea Facciabene
20 May 2013
View more papers

More From: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Paper Title
Journal
Date
Author
Predicting outcomes in malignant ovarian germ cell tumors using the modified International Germ Cell Cancer Collaborative Group classification system
Xinyue Zhang ... Jiaxin Yang
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Xinyue Zhang, et. al.Xinyue Zhang ... Jiaxin Yang
16 Jul 2024
Oncological outcomes after laparotomic, laparoscopic, and robot-assisted laparoscopic staging for early high–intermediate or high-risk endometrial cancer
Ruben C G Koek ... Cornelis G Gerestein
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Ruben C G Koek, et. al.Ruben C G Koek ... Cornelis G Gerestein
16 Jul 2024
Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA
Giorgia Dinoi ... Francesco Fanfani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Giorgia Dinoi, et. al.Giorgia Dinoi ... Francesco Fanfani
13 Jul 2024
Role of V-Y flap reconstruction in vulvar cancer patients: multicenter retrospective study
Violante Di Donato ... Giorgio Bogani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Violante Di Donato, et. al.Violante Di Donato ... Giorgio Bogani
13 Jul 2024
View more papers